Quarterly report pursuant to Section 13 or 15(d)

Goodwill (Tables)

v2.4.1.9
Goodwill (Tables)
 3 Months Ended
Mar. 31, 2015
Acquired Finite-Lived Intangible Assets [Line Items]  
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]
The net carrying value of the identifiable intangible assets as of March 31, 2015 is as follows: 
 
 
 
As of March 31, 2015
 
Life
 
Carrying
Accumulated
 
 
(Years)
 
Amount
Amortization
Net
Diagnostic assets:
 
 
 
 
 
Asuragen acquisition:
 
 
 
 
 
   Thyroid
9
 
$
8,519

$
—

$
8,519

   Pancreas
7
 
2,882

257

2,625

   Biobank
4
 
1,575

246

1,329

RedPath acquisition:
 
 
 
 
 
Pancreas test
7
 
16,141

961

15,180

Barrett's test
9
 
18,351

—

18,351

Total
 
 
$
47,468

$
1,464

$
46,004

Diagnostic lab:
 
 
 
 
 
CLIA Lab
2.3
 
$
609

$
179

$
430

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Estimated amortization expense for the next five years is as follows:
2015
2016
2017
2018
2019
$
5,102

$
6,358

$
6,097

$
5,949

$
5,703